📊 Backtest📒 Journal Updated 29/09/2026
← 🔥 Turbo
📐 Simulate Position
STALE?Report written 62 days ago · at $0.93entry levels may be stale — re-check before acting

CRDF

MoonshotSMALL CAP
Cardiff Oncology, Inc. · NASDAQ · Healthcare / Biotechnology (Oncology)
$0.93
▲ 9.19%
MCap $63.9M
Closed Aug 3, 2026 at $0.93 (+9.19% on the day), still below the Jul 15 $1.05 raise price. The 52-week range has widened further since the Jul 22 report — a new low of $0.7566 was set (vs $0.82 previously), against a $3.31 high. No Q2 2026 earnings/cash update has been published yet as of this writing; the last confirmed cash figure is the Q1 10-Q's $46.1M (plus the ~$9M net from the Jul raise).
BusinessClinical-stage oncology · onvansertib (PLK1 inhibitor) has strong Phase 2 data (72.2% vs 42.1% ORR), but the Nerviano license fight is still unresolved 10+ weeks in, and the newly-detailed Phase 3 ($128–192M) now needs more capital than Cardiff's entire market cap
Thesis

Nothing has resolved since the Jul 22 report — if anything the picture got harder. The Nerviano license dispute (Cardiff sued May 19, 2026; Nerviano issued a termination notice May 27, 2026) is still unresolved 10+ weeks later with no ruling or settlement reported. Worse, a follow-up research note detailing the planned CRDF-005 Phase 3 trial revealed it needs $128–192M to fund — more than double Cardiff's entire ~$64M market cap — and pushed initiation guidance out to 2027, a full year later than the 'H2 2026' language cited in the last report; analysts have already cut probability-of-success from 60% to 50% on the licensing overhang. ⚠️ SURVIVAL: cash is guided only into Q1 2027 (~8 months away) even after the dilutive Jul 15 $10M raise, and that Phase 3 funding gap all but guarantees another, likely much larger, dilutive raise — this is a real near-term survival question layered on top of the litigation risk, not boilerplate. It stays on the speculative radar only because the underlying Phase 2 efficacy data (72.2% vs 42.1% ORR) is genuinely strong and the analyst target spread ($2–$12, avg $5.21–$7.50) prices in real optionality if the litigation breaks Cardiff's way — but the Base case here now assumes continued overhang, not resolution, which is why the upside numbers are sharply lower than the last report's. Extreme, minimal position sizing only.

📝 Primary Verdict · Core Holding
SPECULATIVEMoonshot

ค่าขนม — tiny position only, smaller than the Jul 22 call. Clinical data is still genuinely strong, but the license fight remains unresolved 10+ weeks in and the Phase 3 funding gap ($128-192M vs a $64M market cap) is now an explicit, quantified overhang that wasn't priced in before. Position for total loss.

78
score / 100 ⓘ
⚡ Catalyst
⚖️ Nerviano License Dispute — still unresolvedUNRESOLVED (10+ wks, no ruling)

Cardiff sued Nerviano Medical Sciences on May 19, 2026 seeking a ruling it did not breach the onvansertib license; Nerviano issued a termination notice on May 27, 2026 which Cardiff disputes as ineffective. As of Aug 2026, 10+ weeks later, no court ruling or settlement has been reported — this remains the single biggest swing factor for the stock.

Ongoing
🧬 Phase 3 (CRDF-005) Initiation — pushed to 20272027 (pushed back a year)

A ~640-patient Phase 3 trial (dual ORR/PFS endpoints) is planned following the positive Phase 2 readout, but a follow-up research note now guides initiation to 2027 (not H2 2026) and pegs the funding need at $128–192M — capital Cardiff does not currently have and has not announced a plan to secure.

2027
🎯 Entry Point
Entry 1
$0.93
Current price — already reflects the litigation/dilution overhangScale in (tiny)
Entry 2PREFERRED
$0.7–0.8
Below the fresh 52-week low — best R/R if litigation or financing headlines drive further weaknessIf dips
Entry 3
$0.45
Deep capitulation — only on adverse litigation ruling or a financing crisisDeep dip only
✅ Take Profit
TP1
Base — litigation drags on unresolved, Phase 2 data narrative gets some credit but the 2027 Phase 3 + $128-192M funding gap caps upside
$1.35
+45%
TP2
Bull — license dispute resolves in Cardiff's favor and a non-dilutive or partnership-based Phase 3 funding path emerges
$2.34
+150%
TP3 🌙
Moon — clean license win + Phase 3 funded and initiated + full analyst consensus reached
$5.12
+450%
🔴 Stop Loss
Tight Stop
Below the fresh 52-week low — thesis-neutral but momentum breaking down on litigation/financing risk
$0.7
-24.7%
Hard Stop
Risk-of-zero territory — adverse license ruling or a bankruptcy-adjacent financing event
$0.35
-62.4%
Risk / Reward
From current price ($0.93) tight stop vs TP2
6.1 : 1
⚠ Asymmetric ✅ on paper, but the Nerviano dispute plus the newly-quantified $128-192M funding gap are both existential, not routine biotech risk — 1-2% max position
📅 Estimate Date
Nerviano License Dispute Ruling/Settlement
10+ weeks since Cardiff's suit and Nerviano's termination notice with no resolution reported; binary and existential for the company
Ongoing — no ruling as of Aug 2026
Timeline unknown
Phase 3 (CRDF-005) Initiation
~640-patient trial, dual ORR/PFS endpoints; needs $128–192M not yet secured — pushed back a full year from the H2 2026 guidance cited in the Jul 22 report
2027
Financing plan not yet announced
📈 Possible Up % — Scenario Spread
Bear
-75%
$0.23
Base
+45%
$1.35
Bull
+150%
$2.34
Moon
+450%
$5.12
← downsideupside →
🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed held at 3.50-3.75% on Jul 29, 2026 with 3 hawkish dissents favoring a hike — rate-hike tail risk into year-end hasn't gone away
Inflation
Core PCE still 3.3% YoY, well above the 2% target
Sector Impact
CRDF's litigation and clinical catalysts are idiosyncratic and macro-independent, but the financing overlay compounds directly in a high-rate environment — with a $128-192M Phase 3 funding need against a $64M market cap, every basis point of rate matters to how dilutive the next raise (likely equity, given the going-concern flag) will be.
Summary
Macro risk is secondary here — CRDF's own litigation and financing situation dominates the stock's direction far more than the Fed does, but a hawkish rate backdrop makes the unavoidable next capital raise even more dilutive than it would otherwise be.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (8 analysts, stockanalysis.com)
Buy$5.21+460%
Follow-up research note (post Phase 3 detail)
Buy$7.5+706%
Craig-Hallum
Hold$2+115%
current price $0.93
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

CRDF❌ BadJul 2026
-32%
in 1 day
Jul 15-16, 2026 dilutive $10M registered direct offering at $1.05, priced below prior levels
Direct, sourced same-company precedent for how badly the market punishes financing-driven news here — the stock is still trading below this raise price three weeks later, and the far larger raise implied by the $128-192M Phase 3 funding gap would likely be worse.
CRDF⚡ MixedJun 2026
+2%
in 1 day
Jun 2, 2026 ASCO presentation of positive Phase 2 data (72.2% vs 42.1% confirmed ORR, primary endpoint met)
Same-company precedent showing that even genuinely strong clinical data barely moved the stock — the license overhang has suppressed the normal biotech re-rate pattern, and this dynamic has persisted unchanged through Aug 2026.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-25% / -50%) only when trading the earnings spot — not for the core holding (use the -24.7% / -62.4% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
0% to +10% pre-event drift; frequently flat-to-negative given the license overhang and now-quantified financing gapminimal pre-event runup; litigation and financing news move the stock discretely rather than via anticipatory drift

Clinical-stage nano-caps with pending litigation or license risk typically trade heavy and range-bound rather than running up ahead of resolution — CRDF's own muted +2.03% reaction to genuinely strong Phase 2 data (Jun 2, 2026) shows the license overhang dominating sentiment over the science, and that pattern has persisted through Aug 2026 with no resolution.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +2%
range: 0% to +5% observed on CRDF's own recent win· Jun 2, 2026
CRDF's own Jun 2, 2026 ASCO data (72.2% vs 42.1% confirmed ORR, primary endpoint met) only moved the stock +2.03% on the day — a muted reaction for data this strong, directly illustrating how much the license overhang is suppressing any re-rate even on good news.
❌ Catalyst Missavg -32%
range: -30% to -35%· Jul 15-16, 2026
CRDF's own Jul 15-16, 2026 dilutive $10M registered direct offering at $1.05 triggered a -32.11% single-day decline — a direct, sourced example of how the market punishes financing-driven negative catalysts on this stock specifically, and the template for how a bad litigation ruling or forced next raise would likely trade.
💼Spot Position Sizing
How the recommended % is derived
1%
of portfolio

Going-concern nano-cap with an existential, still-unresolved license dispute AND a newly-quantified $128-192M Phase 3 funding gap against a $64M market cap — 1% caps downside to a tolerable level given the real possibility of the stock going to near-zero or being diluted into irrelevance.

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-25%($0.7)
Below the fresh 52-week low — thesis-neutral but a real warning sign of litigation- or financing-driven capitulation
After Catalyst (Bad Result)-50%
An adverse ruling in the Nerviano dispute, or a forced bankruptcy-adjacent financing, ends the thesis entirely — exit
📎 Sources

Generated 2026-08-04 · Not financial advice